Eyegate Pharma Revenue, Profits - EYEG Annual Income Statement

Add to My Stocks
$0.35 $0 (0%) EYEG stock closing price Sep 20, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Eyegate Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement for EYEG which shows a YOY revenue decline of 0 is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Revenue for year 2017 is $- and has decreased from $- year on year as is evident when you compare the latest figures in the latest Eyegate Pharma profit and loss statement with those of the prior corresponding period. Also see Eyegate Pharma assets and Eyegate Pharma free cash flow for a complete valuation of EYEG stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Eyegate Pharma Revenues or Net Sales
------
Cost Of Goods Sold (COGS)------
Eyegate Pharma Gross Profit
------
Research & Development Expense10.33M8.42M2.71M-1.01M3.03M
Selling General & Admin Expense4.63M5.59M3.96M1.93M2.08M2.81M
Income Before Depreciation Depletion Amortization-14.55M-13.34M-6.67M-2.46M-3.09M-5.85M
Depreciation Depletion Amortization------
Non Operating Income---1.35M--
Interest Expense--1.93M---
Eyegate Pharma Pretax Income
-14.55M-13.34M-8.38M-1.55M-3.68M-5.8M
Provision for Income Taxes-1.34M-----
MinorityInterest------
Investment Gains Losses------
Other Income------
Income Before Extraordinaries & Disc Operations-13.21M-13.34M-8.38M-1.55M-3.68M-5.8M
Extraordinary Items & Discontinued Operations------
Eyegate Pharma Profit/ Loss (Net Income)
-13.21M-13.34M-8.39M-1.77M-3.87M-6.03M
Average Shares used to compute Diluted EPS14.26M8.83M6.16M-5.01M-
Average Shares used to compute Basic EPS14.26M8.83M6.16M-5.01M-
Income Before Nonrecurring Items-14.56M-13.34M-16.62M-2.64M-3.88M-
Income from Nonrecurring Items1.34M-----
Eyegate Pharma Earnings Per Share Basic Net
-0.93-1.51-2.70-9.20-0.76-
Eyegate Pharma Earnings Per Share Diluted Net
-0.93-1.51-2.70-9.20-0.76-
EPS Diluted Before Nonrecurring Items-1.02-1.51-2.70-13.70-0.76-
Preferred Dividends Acc Pd------
Dividends Common------
Dividend Per Share Common0.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Eyegate Pharma stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Eyegate Pharma revenue chart implies that the company is growing. It has not been the case with Eyegate Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Eyegate Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The EYEG financials along with Eyegate Pharma historical stock prices provide a lot of details about the firm.

Eyegate Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
4.24
Dividend Yield
0%